Abstract: Gö 6983 is a potent, fast-acting, and lipid-soluble bisindolylmaleimide analog that functions as a broad-spectrum inhibitor of protein kinase C (PKC). While the provided literature primarily investigates its profound protective effects in myocardial ischemia/reperfusion (I/R) injury and inflammation, its mechanism of action—specifically the modulation of PKC isoforms—highlights its broader therapeutic and research potential, including applications in oncology where PKC signaling regulates cellular proliferation and carcinogenesis. Gö 6983 effectively inhibits classical, novel, and atypical PKC isoforms at nanomolar concentrations, with a unique structural methoxy group enabling the specific inhibition of the atypical PKCζ isoform. Conversely, it is highly ineffective against PKCμ, providing a valuable biochemical tool for differentiating kinase activities. Pharmacologically, Gö 6983 attenuates polymorphonuclear leukocyte (PMN) activation, reduces superoxide radical release, and preserves endothelial function, making it a compound of significant interest for modulating kinase-driven pathological pathways.
1. Introduction
Protein kinase C (PKC) represents a family of phospholipid-dependent serine/threonine protein kinases that play a central role in signal transduction. PKC is intricately involved in the control of numerous cellular processes, including proliferation, differentiation, and carcinogenesis, making it a relevant target in oncology and inflammatory disease research [2]. Gö 6983 (molecular weight = 442.5) is a synthetic bisindolylmaleimide analog of the natural fungal metabolite staurosporine [1] [3]. It is a fast-acting, lipid-soluble compound that acts as a broad-spectrum inhibitor of PKC [1]. In the context of acute cellular stress and tissue injury, Gö 6983 has been extensively characterized for its ability to attenuate polymorphonuclear leukocyte (PMN)-induced myocardial ischemia/reperfusion (I/R) injury, highlighting its potent ability to modulate inflammatory and apoptotic/necrotic cellular responses [1] [3].
2. Pharmacological Activity
Gö 6983 exerts significant protective effects against tissue damage mediated by oxidative stress and inflammation. In isolated perfused rat heart models of PMN-induced myocardial I/R injury, administration of Gö 6983 at concentrations of 50 to 100 nM at the onset of reperfusion significantly restores left ventricular developed pressure (LVDP) and the maximal rate of LVDP (+dP/dtmax) to near baseline values [3]. The compound does not exert direct inotropic effects on cardiac contractile function in non-ischemic tissues [3].
The protective pharmacological profile of Gö 6983 is largely driven by its effects on leukocytes and the vascular endothelium. It significantly reduces PMN adherence to the vascular endothelium and subsequent infiltration into post-ischemic tissue [1] [3]. A major component of this activity is the dose-dependent inhibition of superoxide radical release from activated PMNs, achieving up to 90% inhibition at 100 nM [3]. Furthermore, Gö 6983 augments endothelial-derived nitric oxide (NO) release, which quenches superoxide radicals, attenuates endothelial dysfunction, and promotes vasodilation [1]. Beyond I/R injury, Gö 6983 has also been shown to strongly inhibit antigen-induced superoxide release from human leukocytes in allergic responses and to inhibit intracellular Ca2+ accumulation in vascular tissue [1].
3. Molecular Mechanism of Action
Gö 6983 enters cells via simple diffusion and inhibits PKC by binding directly to its highly conserved ATP-binding site [1] [3]. It is a broad-spectrum inhibitor, effectively suppressing the in vitro kinase activity of classical (α, βI, βII, γ), novel (δ, ε, η), and atypical (ζ) PKC isoforms with IC50 values ranging from 7 to 60 nM [1] [2].
A critical aspect of its mechanism is the inhibition of PKCζ (IC50 = 60 nM), an isoform abundantly expressed in PMNs. PKCζ regulates the activation of NADPH oxidase and stimulates the expression of intercellular adhesion molecule 1 (ICAM-1) on the vascular endothelium [1] [3]. By inhibiting both PKCζ and PKCβII, Gö 6983 prevents the phosphorylation of p47phox, an obligatory step for superoxide generation by NADPH oxidase [1] [3]. Interestingly, while it is highly potent against most PKC isoforms, Gö 6983 is extremely ineffective at inhibiting PKCμ (also known as PKD), requiring micromolar concentrations (IC50 = 20 μM) for suppression [2].
4. Structure-Activity Relationship (SAR)
The chemical structure of Gö 6983 (2-[1-[(3-dimethylaminopropyl)-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)]maleimide) dictates its specific inhibitory profile [1]. Unlike staurosporine, which possesses an intact aromatic ring structure, Gö 6983 and other bisindolylmaleimides feature an opened central aromatic ring. This open ring structure renders them very poor suppressors of PKCμ activity, whereas intact ring compounds (like staurosporine and Gö 6976) effectively inhibit PKCμ [2].
Furthermore, Gö 6983 differs from its prototype analog Gö 6850 (bisindolylmaleimide I) solely by a methoxy group substitution [1]. This specific methoxy group is a critical structural feature; it enables Gö 6983 to inhibit the atypical PKCζ isoform in the low nanomolar range (60 nM). In contrast, Gö 6850 and staurosporine, which lack this methoxy group, require micromolar concentrations to inhibit the PKCζ isoform [1].
5. Current Limitations
A primary limitation of Gö 6983 is the potential loss of kinase selectivity and the onset of cytotoxicity at higher concentrations. While highly effective and protective at 50 to 100 nM, increasing the concentration to 200 nM results in a reduced protective effect, despite near-total (99%) inhibition of PMN superoxide release [3]. At 200 nM, PMN viability decreases, suggesting that the loss of selectivity may lead to increased endothelial and myocyte cell death. This cellular toxicity can paradoxically exacerbate tissue dysfunction by increasing the release of inflammatory cytokines [3]. Consequently, the broad-spectrum action of Gö 6983 requires careful dose titration to ensure successful therapeutic outcomes without inducing cytotoxicity [1].
6. Future Perspectives
Because PKC is centrally involved in cellular proliferation, differentiation, and carcinogenesis, the potent and broad-spectrum PKC inhibitory profile of Gö 6983 holds significant potential for broader applications, including oncology research [2]. In the context of ischemic and inflammatory diseases, Gö 6983 shows promise as a therapeutic agent in organ preservation and perfusion solutions for transplantation surgery, as well as in the treatment of cerebral ischemia (stroke) and severe allergic responses [1]. Additionally, its unique inability to inhibit PKCμ makes Gö 6983 an invaluable biochemical tool for selectively analyzing in vivo PKCμ kinase activity in the presence of other PKC isoenzymes, aiding in the mapping of complex kinase signaling networks [2].
